Literature DB >> 3435131

Predicted and measured aminoglycoside pharmacokinetic parameters in critically ill patients.

E Hassan1, J D Ober.   

Abstract

We conducted a prospective study to determine whether predicted aminoglycoside pharmacokinetic parameters (based on population averages) correlate with measured values in critically ill patients. There was wide interpatient variability for all pharmacokinetic parameters. Only predicted and measured volumes of distribution (18.7 +/- 6.5 versus 22.9 +/- 7.7 liters [mean +/- standard deviation], respectively), with a mean of 0.32 +/- 0.09 liter/kg of dosing body weight, were significantly different. There were no relationships between pharmacokinetic parameters and documented infection, death, or intubation status. The results indicate that volume of distribution is commonly underestimated in intensive care unit patients, whereas elimination rates may be adequately predicted based on population averages. We therefore recommend that aminoglycoside volume of distribution estimates for intensive care unit patients take fluid and adipose excess into account and be based on 0.32 liter/kg rather than the usual 0.25 liter/kg.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3435131      PMCID: PMC175054          DOI: 10.1128/AAC.31.11.1855

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

1.  Gentamicin serum concentrations: pharmacokinetic predictions.

Authors:  J H Hull; F A Sarubbi
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

2.  The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia.

Authors:  R D Moore; C R Smith; P S Lietman
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

3.  Initial aminoglycoside levels in the critically ill.

Authors:  W R Summer; J R Michael; J J Lipsky
Journal:  Crit Care Med       Date:  1983-12       Impact factor: 7.598

4.  Predicting serum gentamicin levels in adult trauma patients.

Authors:  T C Majerus; E S Caplan
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

5.  Gentamicin therapy in renal failure: a nomogram for dosage.

Authors:  R A Chan; E J Benner; P D Hoeprich
Journal:  Ann Intern Med       Date:  1972-05       Impact factor: 25.391

6.  Kinetic model for gentamicin dosing with the use of individual patient parameters.

Authors:  R J Sawchuk; D E Zaske; R J Cipolle; W A Wargin; R G Strate
Journal:  Clin Pharmacol Ther       Date:  1977-03       Impact factor: 6.875

7.  Increased dosage requirements of gentamicin in burn patients.

Authors:  D E Zaske; R J Sawchuk; D N Gerding; R G Strate
Journal:  J Trauma       Date:  1976-10

8.  Rapid gentamicin elimination in obstetric patients.

Authors:  D E Zaske; R J Cipolle; R G Strate; J W Malo; M F Koszalka
Journal:  Obstet Gynecol       Date:  1980-11       Impact factor: 7.661

Review 9.  The aminoglycosides.

Authors:  A M Ristuccia; B A Cunha
Journal:  Med Clin North Am       Date:  1982-01       Impact factor: 5.456

Review 10.  Regulation of the peripheral vasculature and tissue oxygenation in health and disease.

Authors:  F Kreuzer; S M Cain
Journal:  Crit Care Clin       Date:  1985-11       Impact factor: 3.598

View more
  10 in total

1.  Bayesian forecasting of serum gentamicin concentrations in intensive care patients.

Authors:  K A Rodvold; R D Pryka; P G Kuehl; R A Blum; P Donahue
Journal:  Clin Pharmacokinet       Date:  1990-05       Impact factor: 6.447

2.  Appropriate antibiotic dosage levels in the treatment of severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Maya Hites; Marjorie Beumier; Sabino Scolletta; Frédérique Jacobs
Journal:  Curr Infect Dis Rep       Date:  2011-10       Impact factor: 3.725

Review 3.  Antimicrobial treatment of febrile neutropenia: pharmacokinetic-pharmacodynamic considerations.

Authors:  Tiphaine Goulenok; Bruno Fantin
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

4.  Population pharmacokinetics and Monte Carlo dosing simulations of meropenem during the early phase of severe sepsis and septic shock in critically ill patients in intensive care units.

Authors:  Sutep Jaruratanasirikul; Suriyan Thengyai; Wibul Wongpoowarak; Thitima Wattanavijitkul; Kanyawisa Tangkitwanitjaroen; Waroonrat Sukarnjanaset; Monchana Jullangkoon; Maseetoh Samaeng
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

5.  Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock.

Authors:  Fabio Silvio Taccone; Pierre-François Laterre; Herbert Spapen; Thierry Dugernier; Isabelle Delattre; Brice Layeux; Daniel De Backer; Xavier Wittebole; Pierre Wallemacq; Jean-Louis Vincent; Frédérique Jacobs
Journal:  Crit Care       Date:  2010-04-06       Impact factor: 9.097

6.  Increased aminoglycoside dosage requirements in hematologic malignancy.

Authors:  R G Zeitany; N S El Saghir; C R Santhosh-Kumar; M A Sigmon
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

7.  Correlation of the pharmacokinetic parameters of amikacin and ceftazidime.

Authors:  Duangchit Panomvana; Sam-Ang Kiatjaroensin; Danabhand Phiboonbanakit
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

8.  Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.

Authors:  Wei Wei Tan; Kevin M Watt; Felix Boakye-Agyeman; Michael Cohen-Wolkowiez; Yee Hui Mok; Chee Fu Yung; Yoke Hwee Chan
Journal:  J Clin Pharmacol       Date:  2021-01-12       Impact factor: 2.860

9.  Optimal aminoglycoside therapy following the sepsis: how much is too much?

Authors:  Laleh Mahmoudi; Ramin Niknam; Sarah Mousavi; Arezoo Ahmadi; Hooshyar Honarmand; Shadi Ziaie; Mojtaba Mojtahedzadeh
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

10.  Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target.

Authors:  Florencia Palacios; Xiao-Jie Yan; Gerardo Ferrer; Shih-Shih Chen; Stefano Vergani; Xuejing Yang; Jeffrey Gardner; Jaqueline C Barrientos; Philip Rock; Richard Burack; Jonathan E Kolitz; Steven L Allen; Michael G Kharas; Omar Abdel-Wahab; Kanti R Rai; Nicholas Chiorazzi
Journal:  Leukemia       Date:  2021-01-27       Impact factor: 11.528

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.